Akebia Therapeutics (AKBA) Insider Trading & Ownership $1.80 -0.11 (-5.76%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.80 -0.01 (-0.28%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Akebia Therapeutics (NASDAQ:AKBA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.10%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$770,869.56 Get AKBA Insider Trade Alerts Want to know when executives and insiders are buying or selling Akebia Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AKBA Insider Buying and Selling by Quarter Akebia Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/3/2025John P ButlerCEOSell144,250$2.10$302,925.00 2/3/2025Nicholas GrundInsiderSell55,621$2.10$116,804.10 2/3/2025Richard C MalabreCAOSell30,202$2.10$63,424.20 2/3/2025Steven Keith BurkeSVPSell50,506$2.10$106,062.60 2/29/2024John P ButlerCEOSell46,570$1.58$73,580.60 2/29/2024Michel DahanCOOSell8,661$1.58$13,684.38 2/29/2024Nicole R HadasSVPSell5,974$1.58$9,438.92 2/27/2024John P ButlerCEOSell37,733$1.52$57,354.16 2/27/2024Michel DahanCOOSell10,744$1.52$16,330.88 2/27/2024Nicole R HadasSVPSell7,411$1.52$11,264.72 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. (Data available from 1/1/2013 forward) AKBA Insider Trading Activity - Frequently Asked Questions Who is on Akebia Therapeutics's Insider Roster? The list of insiders at Akebia Therapeutics includes David A Spellman, John P Butler, Michel Dahan, Nicholas Grund, Nicole R Hadas, Richard C Malabre, Steven C Gilman, Steven Keith Burke, and Violetta Cotreau. Learn more on insiders at AKBA. What percentage of Akebia Therapeutics stock is owned by insiders? 4.10% of Akebia Therapeutics stock is owned by insiders. Learn more on AKBA's insider holdings. Which Akebia Therapeutics insiders have been selling company stock? The following insiders have sold AKBA shares in the last 24 months: David A Spellman ($6,344.80), John P Butler ($592,805.12), Michel Dahan ($164,460.98), Nicholas Grund ($116,804.10), Nicole R Hadas ($109,260.48), Richard C Malabre ($63,424.20), and Steven Keith Burke ($214,921.77). How much insider selling is happening at Akebia Therapeutics? Insiders have sold a total of 823,227 Akebia Therapeutics shares in the last 24 months for a total of $1,268,021.45 sold. Akebia Therapeutics Key ExecutivesMr. John P. Butler MBA (Age 60)CEO, President & Director Compensation: $1.81M1 recent tradesDr. Steven Keith Burke M.D. (Age 63)Senior VP of Research & Development and Chief Medical Officer Compensation: $937.39k1 recent tradesMr. Erik John Ostrowski M.B.A. (Age 52)Senior VP, CFO & Chief Business Officer Mr. Richard C. Malabre (Age 63)Chief Accounting Officer 1 recent tradesMs. Kimberly GarkoSenior VP & Chief Technical OfficerMs. Tracey VetterickVice President of Portfolio Strategy & Corporate AdministrationMercedes CarrascoSenior Director of Investor & Corporate CommunicationsMs. Carolyn RucciSenior VP of Legal, General Counsel & SecretaryMs. Meredith BowmanSenior VP & Chief People OfficerMr. Nicholas Grund (Age 54)Senior VP & Chief Commercial Officer 1 recent trades More Insider Trading Tools from MarketBeat Related Companies NewAmsterdam Pharma Insider Transactions IDEAYA Biosciences Insider Transactions Schrödinger Insider Transactions Travere Therapeutics Insider Transactions Vera Therapeutics Insider Transactions Iovance Biotherapeutics Insider Transactions Praxis Precision Medicines Insider Transactions Wave Life Sciences Insider Transactions Apogee Therapeutics Insider Transactions Disc Medicine Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:AKBA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKBA Stock Alerts